Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Befotertinib versus icotinib as adjuvant therapy for EGFR-sensitive mutation-positive resected NSCLC
CTR20230429Phase 3Active
- Sponsor
- Betta Pharmaceuticals
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of befotertinib, icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Started Mar 2023; status: active.
02
Drugs
befotertinibicotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20230429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230429.